Reaction Details  Report a problem with these data
Target
Interleukin-2
Ligand
BDBM387261
Substrate
n/a
Meas. Tech.
Inhibition of IL-2 secretion
IC50
<100.0±n/a nM
Citation
 Irlapati, NR; Deshmukh, GK; Karche, VP; Jachak, SM; Sinha, N; Palle, VP; Kamboj, RK Oxazoline and isoxazoline derivatives as CRAC modulators US Patent  US10292981 Publication Date 5/21/2019
Target
Name:
Interleukin-2
Synonyms:
IL-2 | IL2 | IL2_HUMAN | INN=Aldesleukin | Interleukin-2 | Interleukin-2 (IL-2) | T-cell growth factor | TCGF
Type:
Enzyme
Mol. Mass.:
17630.05
Organism:
Homo sapiens (Human)
Description:
P60568
Residue:
153
Sequence:
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
  
Inhibitor
Name:
BDBM387261
Synonyms:
N-(5′- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxazol- 3-yl)-2′-methyl-[1,1′- biphenyl]-4-yl-2,6- difluorobenzamide | US10292981, Example 3
Type:
Small organic molecule
Emp. Form.:
C25H20F2N2O3
Mol. Mass.:
434.4347
SMILES:
Cc1ccc(cc1-c1ccc(NC(=O)c2c(F)cccc2F)cc1)C1=NOC(C)(C)C1=O |t:27|
Structure:
Search PDB for entries with ligand similarity: